论文部分内容阅读
选择１１例正常健康妇女为研究对象，采取受试者自身对照法，分别于羊膜腔注药前１小时、注药后４８小时抽取静脉血常规染色体制片观察。用药前后分别观察了８９２个、８８５个淋巴细胞中期分裂相。用药前后染色体数目畸变率分别为０．３４％和０．２３％，染色体结构畸变率分别为１．１２％和１．６９％；两组结果经统计学处理（ｔ检验），差别无显著意义（Ｐ＞０．０５）；提示使用利凡诺羊膜腔注射终止妊娠时没有可察觉的致癌、致突变等遗传效应。
Eleven normal healthy women were selected as study subjects, and the subjects’ self-control method was adopted. One hour before injection of amniotic fluid and 48 hours after injection of drug, routine venous blood routine was taken for observation. Before and after treatment were observed in 892, 885 lymphocytes metaphase. The number of chromosome aberrations before and after treatment were 0.34% and 0.23% respectively, and the chromosome aberrations were 1.12% and 1.69% respectively. There was no significant difference between the two groups after statistical analysis (t test) (P> 0.05). It is suggested that there is no detectable carcinogenic and mutagenic genetic effects when using Rivanol intracameral injection termination of pregnancy.